Ibiayi Dagogo-Jack

List of Publications by Year
in descending order

66 papers	5,457 citations	218677 26 h-index	144013 57 g-index
66 all docs	66 docs citations	66 times ranked	8002 citing authors

#	Article	IF	Citations
1	Tumour heterogeneity and resistance to cancer therapies. Nature Reviews Clinical Oncology, 2018, 15, 81-94.	27.6	2,149
2	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung Cancer. Cancer Discovery, 2016, 6, 1118-1133.	9.4	919
3	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1199-1206.	1.6	246
4	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	9.4	228
5	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics, 2020, 52, 371-377.	21.4	177
6	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 2017, 1-13.	3.0	158
7	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nature Medicine, 2018, 24, 512-517.	30.7	155
8	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 2535-2545.	7.0	127
9	Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical Cancer Research, 2019, 25, 6662-6670.	7.0	122
10	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	86
11	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clinical Cancer Research, 2019, 25, 158-165.	7.0	81
12	Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. Journal of Thoracic Oncology, 2019, 14, 816-824.	1.1	78
13	Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification. Journal of Thoracic Oncology, 2016, 11, e83-e85.	1.1	75
14	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. Journal of Thoracic Oncology, 2020, 15, 766-776.	1.1	68
15	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, 1530-1538.	1.1	62
16	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusionâ€“Positive Lung Cancer. Clinical Cancer Research, 2021, 27, 2899-2909.	7.0	62
17	Hybrid Captureâ€“Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 255-264.	1.1	53
18	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 258-265.	1.1	53

#	Article	IF	Citations
19	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1497-1506.	1.1	46
20	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer, 2017, 111, 61-64.	2.0	44
21	Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. Journal of Thoracic Oncology, 2018, 13, e226-e227.	1.1	43
22	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21.	5.4	36
23	Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer, 2018, 122, 67-71.	2.0	35
24	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology, 2021, 16, 850-859.	1.1	35
25	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nature Communications, 2021, 12, 5954.	12.8	35
26	Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?. Oncologist, 2016, 21, 662-663.	3.7	26
27	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Journal of Thoracic Oncology, 2019, 14, e226-e228.	1.1	24
28	Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. Journal of Thoracic Oncology, 2016, 11, 1522-1528.	1.1	20
29	Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. Lung Cancer, 2019, 129, 80-84.	2.0	19
30	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	17
31	Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 9611-9611.	1.6	17
32	Association between circulating tumor DNA burden and disease burden in patients with ALKâ€positive lung cancer. Cancer, 2020, 126, 4473-4484.	4.1	14
33	Clinical and Imaging Features of Nonâ€“Small-Cell Lung Cancer in Young Patients. Clinical Lung Cancer, 2021, 22, 23-31.	2.6	14
34	Expanding the Roster of ROS1 Inhibitors. Journal of Clinical Oncology, 2017, 35, 2595-2597.	1.6	12
35	Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation. Journal of Thoracic Oncology, 2020, 15, e174-e176.	1.1	11
36	A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. Journal of Immunotherapy, 2017, 40, 108-113.	2.4	10

#	Article	IF	Citations
37	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precision Oncology, 2022, , .	3.0	10
38	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e155-e157.	1.1	9
39	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	1.1	9
40	Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1441-1451.	2.8	9
41	Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. Oncologist, 2021, 26, 818-824.	3.7	8
42	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinaseâ€“Positive Lung Cancer and CNS-Specific Relapse. JCO Precision Oncology, 2022, 6, e2100522.	3.0	8
43	The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Translational Lung Cancer Research, 2020, 9, 2557-2570.	2.8	6
44	Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS3152-TPS3152.	1.6	5
45	A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression.. Journal of Clinical Oncology, 2020, 38, 9595-9595.	1.6	5
46	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Annual Review of Cancer Biology, 2017, 1, 257-274.	4.5	4
47	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 619-629.	3.8	4
48	Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancerâ€”A Likely Limited Role on a Deep Bench. JAMA Oncology, 2021, 7, 1615.	7.1	4
49	Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS3167-TPS3167.	1.6	4
50	Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer.. Journal of Clinical Oncology, 2021, 39, 243-243.	1.6	3
51	The Role of Liquid Biopsies in Lung Cancer Screening. Seminars in Roentgenology, 2017, 52, 185-187.	0.6	2
52	Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC. Journal of Thoracic Oncology, 2020, 15, 888-890.	1.1	2
53	Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9093-9093.	1.6	2
54	Abstract 5172: B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma. Cancer Research, 2022, 82, 5172-5172.	0.9	2

#	Article	IF	Citations
55	BRAF Mutation Class and Clinical Outcomesâ€"Response. Clinical Cancer Research, 2019, 25, 3189-3189.	7.0	1
56	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. Neuro-Oncology, 2019, 21, vi111-vi111.	1.2	1
57	Retrospective analysis of activity of pembrolizumab (pembro) in melanoma patients (pts) with brain metastasis (BM).. Journal of Clinical Oncology, 2016, 34, 2071-2071.	1.6	1
58	Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2019, 37, 9069-9069.	1.6	1
59	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	1.6	0
60	Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 8536-8536.	1.6	0
61	Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 12083-12083.	1.6	0
62	BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. Journal of Clinical Oncology, 2018, 36, 9045-9045.	1.6	0
63	Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.. Journal of Clinical Oncology, 2019, 37, 9068-9068.	1.6	0
64	Reply to the Letter to the Editor From Zhou etÂal. Journal of Thoracic Oncology, 2020, 15, e136-e137.	1.1	0
65	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-Oncology, 2021, 23, vi49-vi49.	1.2	0
66	Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, e21024-e21024.	1.6	0